Targeting protein degradation without using ubiquitin
Ubiquitin-independent targeted protein degradation
['FUNDING_R01'] · BRANDEIS UNIVERSITY · NIH-10906378
This study is looking at a new way to develop cancer treatments by finding methods to directly break down harmful proteins in the body, which could help make treatments more effective for people with cancer and other diseases.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRANDEIS UNIVERSITY (nih funded) |
| Locations | 1 site (WALTHAM, UNITED STATES) |
| Trial ID | NIH-10906378 on ClinicalTrials.gov |
What this research studies
This research explores a novel approach to drug discovery by focusing on targeted protein degradation, which can potentially lead to more effective cancer treatments. The methodology involves linking a ligand that recognizes the target protein to a ligand that binds to the proteasome, allowing for direct degradation of the protein without relying on the ubiquitin system. This strategy aims to create drugs that can inactivate multiple target proteins simultaneously, potentially improving treatment outcomes for patients with various cancers and other diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers or diseases where traditional drug therapies have been ineffective or where specific protein targets are known to contribute to disease progression.
Not a fit: Patients with conditions that do not involve the targeted proteins or pathways being studied may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of innovative therapies that effectively target and degrade problematic proteins in cancer and other diseases.
How similar studies have performed: While targeted protein degradation is a relatively new approach, preliminary studies have shown promise, indicating that this strategy could lead to significant advancements in treatment options.
Where this research is happening
WALTHAM, UNITED STATES
- BRANDEIS UNIVERSITY — WALTHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HEDSTROM, LIZBETH K. — BRANDEIS UNIVERSITY
- Study coordinator: HEDSTROM, LIZBETH K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.